Topiramate in schizophrenia: A review of effects on psychopathology and metabolic parameters

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 4, 2013, Pages 186-196

  Hahn, Margaret K ^a,b   Cohn, Tony ^a,c   Teo, Celine ^a,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clozapine; Metabolic parameters; Psychopathology; Schizophrenia; Topiramate; Weight gain

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LAMOTRIGINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE SYNTHASE INHIBITOR; OLANZAPINE; PLACEBO; TOPIRAMATE; VALPROIC ACID;

APPETITE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPILEPSY; FATIGUE; GABAERGIC SYSTEM; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLYCEMIC CONTROL; HUMAN; HYPERSALIVATION; INSULIN SENSITIVITY; INTERNEURON; METABOLIC ACIDOSIS; METABOLIC DISORDER; METABOLIC PARAMETERS; MONOTHERAPY; NEGATIVE SYNDROME; NEPHROLITHIASIS; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PSYCHOMOTOR RETARDATION; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; METABOLIC DISEASES; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 84873587102     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.HACO.01062013     Document Type: Review

References (71)

1. Goldberg TE, Weinberger DR. Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Int Clin Psychopharmacol 1995;10 Suppl 3:99-104.
2. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT, Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58(2):165-171.
3. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007;30(3):511-533.
4. Elkis H, Meltzer HY. [Refractory schizophrenia.] Rev Bras Psiquiatr 2007;29 Suppl 2:S41-47. Portuguese.
5. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-872.
6. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995;21(4):579-591.
7. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20(5-6):409-415.
8. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olie JP, et al.Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006;29(1):28-33.
9. (Topomax) T [package insert]. Physicians' Desk Reference. Montvale (NJ): Medical Economics Co, Inc.; 2005
10. Navarro V, Pons A, Romero A, Bernardo M. Topiramate for clozapine-induced seizures. Am J Psychiatry 2001;158(6):968-969.
11. Migliardi G, D'Arrigo C, Santoro V, Bruno A, Cortese L, Campolo D, et al.Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 2007;30(2):107-113.
12. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al.Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142(7):532-546.
13. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
14. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 2001;24(1):43-49.
15. Daskalakis ZJ, Fitzgerald PB, Christensen BK. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Res Rev 2007;56(2):427-442.
16. Thornberg SA, Saklad SR. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 1996;16(1):82-93.
17. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3(5):241-253.
18. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Phar macol Toxicol 2002;42:165-179.
19. Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 2005;78(1):69-86.
20. Klamer D, Engel JA, Svensson L. The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol 2004;503(1-3):103-107.
21. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41 Suppl 1:S3-9.
22. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 Suppl 1:1-93.
23. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.
24. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150(6):1115-1121.
25. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-1696.
26. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60(6):358-363.
27. Bermudes RA, Keck PE, McElroy SL, editors. Managing metabolic abnormalities in the psychiatrically ill: a clinical guide for psychiatrists. Arlington (VA): American Psychiatric Publishing; 2006.
28. Eliasson B, Gudbjornsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 2007;31(7):1140-1147.
29. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007;30(6):1480-1486.
30. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007;9(3):360-368.
31. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10):961-966.
32. Bellinger LL, Williams FE. Aphagia and adipsia after kainic acid lesioning of the dorsomedial hypothalamic area. Am J Physiol 1983;244(3):R389-399.
33. Husum H, Van Kammen D, Termeer E, Bolwig G, Mathe A. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003;28(7):1292-1299.
34. Ha E, Yim SV, Jung KH, Yoon SH, Zheng LT, Kim MJ, et al.Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmacogenomics J 2006;6(5):327-332.
35. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 2005;289(6):E1015-1022.
36. Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al.Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009;23(2):157-162.
37. Muscatello MR, Bruno A, Pandolfo G, Mico U, Bellinghieri PM, Scimeca G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2010;25(5):667-674.
38. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66(8):1012-1015.
39. Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003;26(4):199-206.
40. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24(5):290-294.
41. Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 2010;30(6):706-710.
42. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28(4):169-175.
43. Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010;118(1-3):218-223.
44. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001;15(4):297-301.
45. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry 2002;159(4):675.
46. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry 2003;64(10):1267-1268.
47. Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44(3):339-347.
48. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69(5):636-641.
49. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997;27(1):29-32.
50. Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, et al.Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52(2):321-327.
51. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003;54(2-3):171-178.
52. Huppertz HJ, Quiske A, Schulze-Bonhage A. [Cognitive impairments due to add-on therapy with topiramate.] Nervenarzt 2001;72(4):275-280. German.
53. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6(3):373-381.
54. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72(1):5-9.
55. Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001;132(1):112-114.
56. Ko CH, Kong CK. Topiramate-induced metabolic acidosis: report of two cases. Dev Med Child Neurol 2001;43(10):701-704.
57. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82(1):115-117.
58. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45(2):198.
59. Levy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14(2):e234-239.
60. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002;63(11):1045.
61. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005;59(5):613-615.
62. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70(7):1041-1050.
63. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-1376.
64. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-1087.
65. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
66. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64.
67. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70(1):1-17.
68. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35(7):1520-1530.
69. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7(3):207-211.
70. Jardemark KE, Konradsson A, Schilstrom B, Marcus MM, Svensson TH. Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. Synapse 2009;63(10):913-920.
71. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 1989;99 Suppl:S68-72.